Myriad Genetics, Inc. announced a strategic collaboration with Illumina, Inc. for Illumina to create a kit-based version of the myChoice companion diagnostic test for international markets. The strategic partnership with Myriad and Illumina consists of a time-limited exclusive agreement for Illumina to provide a kit-based version of the myChoice CDx test for international markets. Illumina will leverage its sequencing instrument install base and knowledge from increasing market adoption of its TruSight Oncology 500 next-generation sequencing assay to develop and commercialize distributed kits globally for the assessment of homologous recombination deficiency along with other proprietary biomarkers while Myriad expands access and extends the reach of myChoice CDx through Myriad's services offering.

The myChoice CDx offering through Myriad's world-class laboratory is the only companion diagnostic test extensively validated in clinical trials to predict response to poly-ADP ribose polymerase inhibitor drugs commonly used in the treatment of ovarian, breast, pancreatic and prostate cancer. It utilizes proprietary technologies to measure genomic instability within tumors and help predict drug response. myChoice CDx test recently received both European CE Marking and Japanese regulatory approval for use as a companion diagnostic with Lynparza (olaparib) for first-line maintenance treatment in ovarian cancer in conjunction with bevacizumab.

Lynparza is a PARP inhibitor jointly developed and commercialized by AstraZeneca and Merck.